Literature DB >> 24071004

BP control and left ventricular hypertrophy regression in children with CKD.

Juan C Kupferman1, Lisa Aronson Friedman, Christopher Cox, Joseph Flynn, Susan Furth, Bradley Warady, Mark Mitsnefes.   

Abstract

In adult patients with CKD, hypertension is linked to the development of left ventricular hypertrophy, but whether this association exists in children with CKD has not been determined conclusively. To assess the relationship between BP and left ventricular hypertrophy, we prospectively analyzed data from the Chronic Kidney Disease in Children cohort. In total, 478 subjects were enrolled, and 435, 321, and 142 subjects remained enrolled at years 1, 3, and 5, respectively. Echocardiograms were obtained 1 year after study entry and then every 2 years; BP was measured annually. A linear mixed model was used to assess the effect of BP on left ventricular mass index, which was measured at three different visits, and a mixed logistic model was used to assess left ventricular hypertrophy. These models were part of a joint longitudinal and survival model to adjust for informative dropout. Predictors of left ventricular mass index included systolic BP, anemia, and use of antihypertensive medications other than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Predictors of left ventricular hypertrophy included systolic BP, female sex, anemia, and use of other antihypertensive medications. Over 4 years, the adjusted prevalence of left ventricular hypertrophy decreased from 15.3% to 12.6% in a systolic BP model and from 15.1% to 12.6% in a diastolic BP model. These results indicate that a decline in BP may predict a decline in left ventricular hypertrophy in children with CKD and suggest additional factors that warrant additional investigation as predictors of left ventricular hypertrophy in these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24071004      PMCID: PMC3871770          DOI: 10.1681/ASN.2012121197

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  30 in total

Review 1.  Left ventricular hypertrophy as a predictor of cardiovascular risk.

Authors:  Philippe Gosse
Journal:  J Hypertens Suppl       Date:  2005-04

2.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

3.  Reduced systolic myocardial function in children with chronic renal insufficiency.

Authors:  Marcello Chinali; Giovanni de Simone; Maria Chiara Matteucci; Stefano Picca; Antonio Mastrostefano; Ali Anarat; Salim Caliskan; Nikola Jeck; Thomas J Neuhaus; Amira Peco-Antic; Licia Peruzzi; Sara Testa; Otto Mehls; Elke Wühl; Franz Schaefer
Journal:  J Am Soc Nephrol       Date:  2007-01-10       Impact factor: 10.121

4.  Left ventricular abnormalities in children, adolescents and young adults with renal disease.

Authors:  L M Johnstone; C L Jones; L E Grigg; J L Wilkinson; R G Walker; H R Powell
Journal:  Kidney Int       Date:  1996-09       Impact factor: 10.612

Review 5.  Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge.

Authors:  Adeera Levin
Journal:  Kidney Int Suppl       Date:  2002-05       Impact factor: 10.545

6.  Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors.

Authors:  M M Mitsnefes; S R Daniels; S M Schwartz; R A Meyer; P Khoury; C F Strife
Journal:  Pediatr Nephrol       Date:  2000-09       Impact factor: 3.714

7.  Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

Authors:  Richard B Devereux; Björn Dahlöf; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine E Harris; Jonathan M Edelman; Kristian Wachtell
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

8.  Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight.

Authors:  G de Simone; S R Daniels; R B Devereux; R A Meyer; M J Roman; O de Divitiis; M H Alderman
Journal:  J Am Coll Cardiol       Date:  1992-11-01       Impact factor: 24.094

9.  Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.

Authors:  Sante D Pierdomenico; Domenico Lapenna; Franco Cuccurullo
Journal:  Am J Hypertens       Date:  2008-02-07       Impact factor: 2.689

10.  Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study.

Authors:  Joseph T Flynn; Mark Mitsnefes; Christopher Pierce; Steven R Cole; Rulan S Parekh; Susan L Furth; Bradley A Warady
Journal:  Hypertension       Date:  2008-08-25       Impact factor: 10.190

View more
  39 in total

1.  Urologic care and progression to end-stage kidney disease: a Chronic Kidney Disease in Children (CKiD) nested case-control study.

Authors:  D I Chu; A G Abraham; G E Tasian; M R Denburg; M E Ross; S A Zderic; S L Furth
Journal:  J Pediatr Urol       Date:  2019-03-16       Impact factor: 1.830

2.  Cardiovascular Disease Risk Factors and Left Ventricular Hypertrophy in Girls and Boys With CKD.

Authors:  Rebecca L Ruebner; Derek Ng; Mark Mitsnefes; Bethany J Foster; Kevin Meyers; Bradley Warady; Susan L Furth
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-14       Impact factor: 8.237

Review 3.  Hypertension in Pediatric Dialysis Patients: Etiology, Evaluation, and Management.

Authors:  Raj Munshi; Joseph T Flynn
Journal:  Curr Hypertens Rep       Date:  2018-06-08       Impact factor: 5.369

4.  Prognostic Value of Ambulatory Blood Pressure Load in Pediatric CKD.

Authors:  Jason Lee; Charles E McCulloch; Joseph T Flynn; Joshua Samuels; Bradley A Warady; Susan L Furth; Divya Seth; Barbara A Grimes; Mark M Mitsnefes; Elaine Ku
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-11       Impact factor: 8.237

5.  Assessing longitudinal trends in cardiac function among pediatric patients with chronic kidney disease.

Authors:  Ylva Tranæus Lindblad; Georgios Vavilis; Jonas Axelsson; Maria Herthelius; Peter Bárány
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

6.  Cardiovascular Phenotypes in Children with CKD: The 4C Study.

Authors:  Franz Schaefer; Anke Doyon; Karolis Azukaitis; Aysun Bayazit; Nur Canpolat; Ali Duzova; Ana Niemirska; Betul Sözeri; Daniela Thurn; Ali Anarat; Bruno Ranchin; Mieczyslav Litwin; Salim Caliskan; Cengiz Candan; Esra Baskin; Ebru Yilmaz; Sevgi Mir; Marietta Kirchner; Anja Sander; Dieter Haffner; Anette Melk; Elke Wühl; Rukshana Shroff; Uwe Querfeld
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-08       Impact factor: 8.237

7.  Estimated kidney function in children and young adults with spina bifida: A retrospective cohort study.

Authors:  David I Chu; Lauren C Balmert; Cameron M Arkin; Theresa Meyer; Ilina Rosoklija; Belinda Li; Kavita S Hodgkins; Susan L Furth; Earl Y Cheng; Elizabeth B Yerkes; Tamara Isakova
Journal:  Neurourol Urodyn       Date:  2019-07-08       Impact factor: 2.696

Review 8.  Treatment of hypertension in children with chronic kidney disease.

Authors:  Susan Halbach; Joseph Flynn
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

9.  Twenty-Four-Hour Ambulatory Blood Pressure versus Clinic Blood Pressure Measurements and Risk of Adverse Outcomes in Children with CKD.

Authors:  Elaine Ku; Charles E McCulloch; Bradley A Warady; Susan L Furth; Barbara A Grimes; Mark M Mitsnefes
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-13       Impact factor: 8.237

Review 10.  Evidence-based guidelines for the management of hypertension in children with chronic kidney disease.

Authors:  Janis M Dionne
Journal:  Pediatr Nephrol       Date:  2015-03-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.